Advertisement

Arthritis Res Ther

, 5:9 | Cite as

Albumin-based drug delivery as novel therapeutic approach for rheumatoid arthritis

  • A Wunder
  • U Muller-Ladner
  • E Stelzer
  • E Neumann
  • H Sinn
  • S Gay
  • C Fiehn
Oral presentation

Keywords

Rheumatoid Arthritis Arthritis Albumin Methotrexate Rheumatoid Arthritis Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

We reported recently that albumin is a suitable drug carrier for targeted delivery of methotrexate (MTX) to tumors. Due to pathophysiological conditions in neoplastic tissue, high amounts of albumin accumulate in tumors and are metabolized by malignant cells. MTX, covalently coupled to human serum albumin (MTX-HSA) for cancer treatment, is currently being evaluated in phase II clinical trials. Because the synovium of patients with rheumatoid arthritis (RA) shares various features observed also in tumors, albumin-based drug targeting of inflamed joints might be an attractive therapeutic approach. Therefore, the pharmacokinetics of albumin and MTX in a mouse model of arthritis was examined. Additionally, uptake of albumin by synovial fibroblasts of RA patients and the efficacy of MTX and MTX-HSA in arthritic mice were studied. The results show that, when compared with MTX, significantly higher amounts of albumin accumulate in inflamed paws, and significantly lower amounts of albumin are found in the liver and the kidneys. The protein is metabolized by human synovial fibroblasts in vitro and in vivo. MTX-HSA was significantly more effective in suppression of the onset of arthritis in mice than was MTX. In conclusion, albumin appears to be a suitable drug carrier in RA, most probably due to effects on synovial fibroblasts, which might increase the therapeutic efficacy of and reduce side effects of MTX.

Copyright information

© BioMed Central Ltd 2003

Authors and Affiliations

  • A Wunder
    • 1
  • U Muller-Ladner
    • 2
  • E Stelzer
    • 3
  • E Neumann
    • 2
  • H Sinn
    • 1
  • S Gay
    • 4
  • C Fiehn
    • 5
  1. 1.Department of Radiochemistry and RadiopharmacologyGerman Cancer Research CenterHeidelbergGermany
  2. 2.Department of Internal Medicine IUniversity of RegensburgRegensburgGermany
  3. 3.Cell Biophysics/Cell Biology ProgramEuropean Molecular Biology Laboratory HeidelbergHeidelbergGermany
  4. 4.WHO Collaborating Center for Molecular Bioliology and Novel Therapeutic Strategies for Rheumatic DisordersUniversity of ZurichZurichSwitzerland
  5. 5.Clinic of Internal Medicine VUniversity of HeidelbergHeidelbergGermany

Personalised recommendations